↓ Skip to main content

A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer

Overview of attention for article published in Frontiers in oncology, September 2021
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter
4 X users

Citations

dimensions_citation
38 Dimensions

Readers on

mendeley
22 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
Published in
Frontiers in oncology, September 2021
DOI 10.3389/fonc.2021.744956
Pubmed ID
Authors

Alessio Bruni, Vieri Scotti, Paolo Borghetti, Stefano Vagge, Salvatore Cozzi, Elisa D’Angelo, Niccolò Giaj Levra, Alessandra Fozza, Maria Taraborrelli, Gaia Piperno, Valentina Vanoni, Matteo Sepulcri, Marco Trovò, Valerio Nardone, Elisabetta Lattanzi, Said Bou Selman, Federica Bertolini, Davide Franceschini, Francesco Agustoni, Barbara Alicja Jereczek-Fossa, Stefano Maria Magrini, Lorenzo Livi, Frank Lohr, Andrea Riccardo Filippi

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 22 100%

Demographic breakdown

Readers by professional status Count As %
Other 3 14%
Student > Doctoral Student 3 14%
Student > Bachelor 3 14%
Researcher 3 14%
Student > Master 1 5%
Other 3 14%
Unknown 6 27%
Readers by discipline Count As %
Medicine and Dentistry 11 50%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Sports and Recreations 1 5%
Biochemistry, Genetics and Molecular Biology 1 5%
Neuroscience 1 5%
Other 1 5%
Unknown 6 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 June 2022.
All research outputs
#15,751,285
of 25,392,582 outputs
Outputs from Frontiers in oncology
#4,974
of 22,436 outputs
Outputs of similar age
#220,371
of 435,691 outputs
Outputs of similar age from Frontiers in oncology
#258
of 1,446 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,436 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 435,691 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,446 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.